Vera Therapeutics KOL Event to Discuss Phase 2b Data: Atacicept for the Treatment of IgA Nephropathy (IgAN)
About The Event
Join us for a virtual KOL event with Vera Therapeutics, featuring Jonathan Barratt, PhD, FRCP (University of Leicester) who, together with Vera Therapeutics management, will provide an update on atacicept’s Phase 2b data in IgA nephropathy (IgAN).
Atacicept is a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to IgAN and certain other autoimmune diseases.
A live question and answer session will follow the formal presentations.